首页> 美国卫生研究院文献>International Medical Case Reports Journal >Dupilumab Induced Limbal Stem Cell Deficiency
【2h】

Dupilumab Induced Limbal Stem Cell Deficiency

机译:Dupilumab诱导寿命干细胞缺乏

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Dupilumab is a monoclonal antibody that is used for the treatment of atopic dermatitis (AD) in adults. However, increasing reports of ocular complications including conjunctivitis and dry eye disease have been documented. In this report, we describe a case of a patient who developed limbal stem cell deficiency (LSCD) after prolonged Dupilumab use. A 56-year-old Caucasian male with a history of AD presented with gradual onset cloudy vision and extensive diffuse symblepharon resulting from Dupilumab treatment. He was diagnosed with cicatrizing blepharoconjunctivitis and secondary LSCD after slit lamp examination. In conclusion, LSCD secondary to cicatricial disease is a severe adverse ocular complication caused from long-term Dupilumab treatment.
机译:Dupilumab是一种单克隆抗体,用于治疗成人的特应性皮炎(AD)。然而,已经记录了增加了在包括结膜炎和干眼症中的眼部并发症的报告。在本报告中,我们描述了在延长杜帕里姆人使用后开发了突出干细胞缺乏(LSCD)的患者的情况。一名56岁的白种人男性,具有逐渐发作的广告历史,杜帕里姆人治疗逐渐发作的多云视觉和广泛的弥漫性搅拌乳蛋白。他被诊断为缝隙灯检查后患有瘢痕疙瘩肺癌和次级LSCD。总之,二次患有光谱疾病的LSCD是一种严重的不良眼性并发症,从长期杜比拉姆治疗造成的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号